Sanofi Paying Up to $500 Million for BiPar Sciences
Sanofi-aventis (NYSE: SNY) has agreed to acquire BiPar Sciences Inc., a Brisbane, Calif.-based developer of PARP inhibitors as cancer therapies. The deal could be worth up to $500 million, based on the achievement of milestones for BiPar's lead candidate. BiPar has raised around $60 million in VC funding, from firms like Domain Associates, Canaan Partners, Vulcan Capital, PolyTechnos Venture-Partners, Asset Management Company and Quantum Technology Partners. It also has raised venture debt from Lighthouse Capital Partners.
15 April 2009•4 mins read
